By controlling the nuclear factor of activated T cells (NFAT1) and interferon regulatory factor 1 (IRF1) pathways, elevated insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) promotes the progression of GC both in vivo and in vitro. This evidence concerns the gene NFATC2 and gastric cancer.